Pharmaceutical Processing | Alvotech to invests $250M in the development of biosimilar monoclonal antibodies News-Medical.net Alvotech, a powerful new player in the field of biopharmaceuticals, today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. Alvotech's current biosimilar assets include ... Alvotech Invests $250 Million in Biopharmaceuticals Alvotech Invests $250M in Biopharmaceuticals Alvogen Pumping $250M into Developing Biosimilars, with New Iceland Plant |
